15 Best Performing ETFs of 2019
As 2019 comes to a close, it’s time to take one more look at the best-performing ETFs. Based on this…
SBIO
ALPS Medical Breakthroughs ETF
$42.44 +$0.07
(+0.17%)
As of 1:00:00 AM EDT | 1/17/20 | Market Closed
SBIO Trading Data
Open
$42.53
Low Price
$42.28
High Price
$42.75
Previous Last Price
$42.37
Bid Size
$0 X 0
Ask Size
$0 X 0
SBIO Portfolio Data
AUM
$224,614,000
Shares
5,300
PE Ratio
0
Price / Book Ratio
3.92
Expense Ratio
0.5
Net Asset Value
$42.38
Volume
Volume
50,800
Avg. Volume (YDT)
72,892
Dollar Volume
$3,390,064
Weekly Avg. Volume
72,360
Monthly Avg. Volume
64,110
Quarterly Avg. Volume
48,860
SBIO Fund Description
The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States. It invests in the stocks of companies operating in the biotechnology and pharmaceutical sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
SBIO Chart
SBIO Summary
Fund Family
ALPS Holdings
Tracks This Index
ALPS Medical Breakthroughs ETF
Inception Date
2015-01-05
Asset Class
Portfolio-Multi Asset
Asset Class Size
Healthcare
SBIO Classification
Region (General)
Global
Region (Specific)
Sector
Health Care
Equity Index
Leveraged Family
SBIO Holdings
Top 10 Holdings
Bluebird Bio Inc. (BLUE)
4.87%
Global Blood Therapeutics Inc. (GBT)
4.52%
MorphoSys AG (MOR)
3.75%
United Therapeutics Corp. (UTHR)
3.66%
Immunomedics Inc. (IMMU)
3.51%
FibroGen Inc. (FGEN)
3.47%
Mirati Therapeutics Inc. (MRTX)
3.43%
Deciphera Pharmaceuticals Inc. (DCPH)
3.18%
Intercept Pharmaceuticals Inc. (ICPT)
3.11%
Allakos Inc. (ALLK)
2.99%
Total SBIO Holdings
Total Holdings: 72
Bluebird Bio Inc. (BLUE)
4.87%
Global Blood Therapeutics Inc. (GBT)
4.52%
MorphoSys AG (MOR)
3.75%
United Therapeutics Corp. (UTHR)
3.66%
Immunomedics Inc. (IMMU)
3.51%
FibroGen Inc. (FGEN)
3.47%
Mirati Therapeutics Inc. (MRTX)
3.43%
Deciphera Pharmaceuticals Inc. (DCPH)
3.18%
Intercept Pharmaceuticals Inc. (ICPT)
3.11%
Allakos Inc. (ALLK)
2.99%
PTC Therapeutics Inc. (PTCT)
2.97%
Alkermes PLC (ALKS)
2.72%
Acceleron Pharma Inc. (XLRN)
2.67%
uniQure NV (QURE)
2.59%
Karuna Therapeutics Inc. (KRTX)
2.44%
Apellis Pharmaceuticals Inc. (APLS)
2.32%
ChemoCenyx Inc. (CCXI)
2.28%
Epizyme Inc. (EPZM)
2.18%
Arena Pharmaceuticals Inc. (ARNA)
2.1%
Eidos Therapeutics Inc. (EIDX)
1.86%
Principia Biopharma Inc. (PRNB)
1.85%
Ironwood Pharmaceuticals Inc. (IRWD)
1.77%
Fate Therapeutics Inc. (FATE)
1.74%
Zymeworks Inc. (ZYME)
1.73%
Akcea Therapeutics Inc. (AKCA)
1.44%
Ligand Pharmaceuticals Inc. (LGND)
1.42%
Cortexyme Inc. (CRTX)
1.41%
SpringWorks Therapeutics Inc. (SWTX)
1.37%
Alector Inc. (ALEC)
1.32%
Dicerna Pharmaceuticals Inc. (DRNA)
1.31%
Constellation Pharmaceuticals Inc. (CNST)
1.23%
Orchard Therapeutics PLC (ORTX)
1.22%
Coherus Biosciences Inc. (CHRS)
1.21%
Madrigal Pharmaceuticals Inc. (MDGL)
1.18%
Enanta Pharmaceuticals Inc. (ENTA)
1.02%
Portola Pharmaceuticals Inc. (PTLA)
0.98%
Rocket Pharmaceuticals Inc. (RCKT)
0.94%
XBiotech Inc. (XBIT)
0.9%
G1 Therapeutics Inc. (GTHX)
0.85%
Gossamer Bio Inc. (GOSS)
0.85%
Krystal Biotech Inc. (KRYS)
0.8%
Aprea Therapeutics Inc. (APRE)
0.75%
Vericel Corp. (VCEL)
0.71%
Frequency Therapeutics Inc. (FREQ)
0.69%
MeiraGTx Holdings PLC (BFYQFJ)
0.67%
UroGen Pharma Ltd. (URGN)
0.64%
ImmunoGen Inc. (IMGN)
0.62%
Replimune Group Inc. (REPL)
0.61%
Kura Oncology Inc. (KURA)
0.52%
Crinetics Pharmaceuticals Inc. (CRNX)
0.52%
Akero Therapeutics Inc. (AKRO)
0.52%
Oyster Point Pharma Inc. (OYST)
0.51%
MacroGenics Inc. (MGNX)
0.5%
Agenus Inc. (AGEN)
0.49%
Viking Therapeutics Inc. (VKTX)
0.47%
Voyager Therapeutics Inc. (VYGR)
0.46%
Rigel Pharmaceuticals Inc. (RIGL)
0.44%
Merus NV (MRUS)
0.43%
Assembly Biosciences Inc. (ASMB)
0.42%
Catalyst Pharmaceuticals Inc. (CPRX)
0.39%
PDL BioPharma Inc. (PDLI)
0.34%
Puma Biotechnology Inc. (PBYI)
0.34%
CytomX Therapeutics Inc. (CTMX)
0.31%
KalVista Pharmaceuticals Inc. (KALV)
0.3%
Albireo Pharma Inc. (ALBO)
0.29%
MediciNova Inc. (MNOV)
0.28%
Concert Pharmaceuticals Inc. (CNCE)
0.22%
XOMA Corp. (XOMA)
0.21%
GlycoMimetics Inc. (GLYC)
0.19%
ALPS Medical Breakthroughs ETF (SBIO)
0%
Cash Equivalent
0%
Corium International Inc. (CORI-CVR)
0%
SBIO Technicals
Alpha
5.04
Beta
1.63
Leverage
Long
Standard Deviation
3.03
SBIO Dividends
Dividend Date
2019-12-19
Latest Dividend
0.016
Annual Dividend
0.02
Annual Dividend Rate
0.02
Annual Dividend Yield
0.04
SBIO Performance
YTD Return
0.38%
1 Year Return
30.5%
3 Year Return
82.93%
5 Year Return
57.83%
10 Year Return
70.85%
SBIO Related Articles
ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength…
Biotech ETFs Jump: Keep an Eye on XBI, IBB & SBIO
Biotech ETFs are movin’ on up on news that Pfizer is buying Array BioPharma for over $10 billion. SPDR S&P Biotech…
Biotech ETFs Are Breaking Out on Pfizer’s Array Biopharma Deal
Biotech sector exchange traded funds rallied Monday after Pfizer (NYSE: PFE) said it would acquire Array Biopharma Inc. (NasdaqGS: ARRY)…
3 Biotech Sector ETFs Bucked the Risk-Off Trend
While the rest of the markets retreated on a round of risk-off selling in response to President Donald Trump’s threats…
A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has…
© 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.